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Overview of Bone Quality Issues
Bone strength is determined by the bone quantity, quality and 
their turnover. In children, the causes leading to their disturbance 
can be numerous. They can be due to the disorders of bone 
mineral homeostasis, imbalance of bone remodeling, disorders of 
collagen and drug related issues affecting calcium absorption. 
A multidisciplinary team involving paediatricians, endocrinolo-
gists, geneticists, and orthopaedic surgeons can help to provide 
a comprehensive treatment for these children. It is important 
to assess the patients thoroughly through history taking, physi-
cal examination, laboratory tests and radiological assessment to 
determine the underlying cause.
Some of the causes are amenable to treatment e.g. rickets can be 
better controlled by proper dietary and supplements together with 
regular monitoring. However, some of the causes e.g. osteogen-
esis imperfecta cannot be fully corrected. The bone quality can 
instead be improved by proper education for fracture prevention, 
pharmacological treatment, and surgical intervention.
Osteogenesis imperfecta
Osteogenesis imperfecta (OI) is an inheritable bone fragility 
disease classically known to be due to type I collagen abnormality. 
The type I collagen abnormality results in reduced bone strength. 
Depending on the severity of involvement, the severely affected 
patients may present with repeated fractures shortly after birth, 
short stature, and multiple deformities in the limbs and spine.
The disease is classiﬁed by Sillence into 4 types according to their 
clinical presentation1. With better understanding of the disease 
in particular the genetic mutation2, the classiﬁcation of OI has 
expanded to 16 types over the past decade3-5.
At the moment, there is no medical treatment that can correct the 
underlying abnormality in OI. However, by either (1) inhibit-
ing the action of osteoclast to reduce the rate of bone resorption 
or (2) increase bone production by the osteoblasts can help to 
improve bone formation. There is a good evidence supporting the 
use of bisphosphonate to improve the bone mineral density in 
particular the severe form. However, whether bisphosphonate can 
reduce fracture rate remains inconsistent6.
Bisphosphonate is the most commonly used medication in OI to 
improve the bone mineral density7,8. Treatment can be started 
as soon as the baby is given birth and continue until skeletal ma-
turity. Regular monitoring of the clinical response and the bone 
mineral density are important. The commonly used bisphospho-
nates include pamidronate and zoledronic acid9-12. Their effect 
in improving the bone mineral density is fairly similar.
Scoliosis in OI
Scoliosis is common in OI and the severity increases with age. 
The more severe the scoliosis, the more likely it would affect 
the lung function13. It is estimated that about 25% of the OI 
patients aged between 1-5 have scoliosis. The number rises to as 
high as 80% in the OI patients > 12 years of age14. Not all OI 
patients’ scoliosis progress that same. It is recognized that the 
more severely affected patients will have higher rate of deteriora-
tion (Type I: 1 degree per year; Type III: 6 degrees per year and 
Type IV: 4 degrees per year)15. The use of bisphosphonate can 
greatly improve the deterioration rate in Type III patients15.
Future Development
With better understanding of the pathogenesis of osteogenesis 
imperfecta, new treatment approaches are currently developing. 
These include antibodies against sclerostin and anti-TGF-b16,17. 
Both have good pre-clinical examination results and are currently 
on clinical trial.
Conclusion
Bone strength is governed by the bone quantity, quality and turn 
over. Any disturbance will result in reduced bone strength leading 
to bone fragility. Finding out the underlying cause of the bone 
fragility is the most important part in managing these children. 
Through proper diet, calcium, vitamin D supplement, and 
antiresportive agents e.g. bisphosphonate, the bone quality can be 
corrected.
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Optimization of Bone Health in Adult Patients in 
Preparation for Surgery
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Bone strength is critical to successful spine surgery. (10-12). 
Strength is a combination of bone quantity and quality. Quantity 
is measured by DXA and CT. Bone quality is related to colla-
gen and mineral status, micro-architecture, and bone turnover 
dynamics. Laboratory analysis best deﬁnes normal and abnormal 
quality. Several laboratory markers can identify bone at risk. 
Bone density is an area measurement of bone mass at the spine 
and hip. Scoliosis inserts artifacts to the analysis and spine density 
measurements should not be used if the curve is over 30 degrees 
and/or there is osteoarthritis of the facet joints. Although there 
is only moderate relationship of the hip and spine densities, hip 
provides a good approximation of bone mass. Alternatively one 
can use a quantitative CT of the vertebra. It measures speciﬁcally 
the trabecular bone and will not be inﬂuenced by osteoarthritis of 
curve. Osteopenic bone (T -1.0 to -2.4) and especially osteo-
porotic (T worse than -2.5) bone lacks good purchase of spinal 
instrumentation and has a high risk for adjacent level compres-
sion fracture. 
Bone quality is compromised in the face of low Vitamin D 
(25-OHvitamin D < 30ng/ml), low calcium (<9.2) and low bone 
speciﬁc alkaline phosphatase (<6.) (10-12). Vitamin D has many 
functions including mineralization of bone and muscle function. 
(4). Vitamin D is best measured by determining the 25(OH)vita-
min D levels. Values below 30ng/ml compromise bone formation 
and mineralization. Values below 45ng/ml interfere with muscle 
related strength and speed as well as balance. 2000 to 4000 inter-
national units of vitamin D3 will correct vitamin D levels in 2 to 
4 weeks and should be part of preoperative treatment.
Calcium is needed for cell function and mineral formation (4,10 
– 12). Calcium and PTH have a close relationship. When calcium 
is low the PTH is high and resorbs calcium from the skeleton to 
remedy the deﬁciency. When calcium is high PTH is turned off. 
Thus by measuring the PTH one can discern the appropriate cal-
cium need. If the PTH is over 50 there is a calcium deﬁciency, if 
below 20 there is a surplus of calcium and in the normal state the 
PTH should be around 30. The usual calcium requirement is 500 
to 750 mg of calcium citrate per day in divided doses. Calcium C 
is better absorbed and prevents kidney stones. 
Alkaline phosphatase is needed to mineralize the bone. There is 
an entity of hypophosphatasia where the bone speciﬁc alkaline 
phosphatase is less than 6. It interferes with growth, leads to 
premature loss of teeth and results in stress fractures. If vitamin 
B6 is elevated then there is the possibility that the patient has the 
genetic defect of inadequate levels of BSAP. 
Collagen is critical to bone strength. It provides tensile strength. 
Most fractures result from bone failing in tension. It can be 
suspected in individuals who present with hypermobility in their 
ﬁngers, elbows, ﬂat feet and ease of touching their feet. Vitamin 
